Alzheimer's Prevention

GHR is working with leading global experts to prioritize detecting and treating Alzheimer’s earlier to delay or prevent cognitive decline.

Partner Spotlights

The Dominantly Inherited Alzheimer’s Network Trials

C2N Diagnostics

By 2050 Alzheimer’s disease prevalence is projected to reach 139 million people globally. In 2024, the cost to the U.S. health system alone was approximately $360 million. We have the chance to dramatically improve diagnosis, prevent symptoms and improve the lives of patients and their caregivers.

GHR partnered with Washington University and C2N Diagnostics to develop a blood test to increase the accuracy and accessibility of an Alzheimer’s diagnosis. C2N Diagnostics developed a blood test that proved 90% accurate in primary care settings according to clinical research published in the Journal of the American Medical Association.

The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) was launched by researchers at Washington University with support from GHR Foundation in 2013 as the first-ever Alzheimer’s prevention trial. Results showed it is possible to remove plaque, reduce tangle formation and slow neurodegeneration. This research was conducted in partnership with families who are genetically predisposed to experience early onset dementia.

The Dominantly Inherited Alzheimer’s Network Tau Next Generation (DIAN Tau NextGen) trial launched in 2021 and is the first trial to simultaneously treat plaques and tangles in the brain.

In 2021, DIAN families began enrolling in the Primary Prevention trial, the first trial to try to prevent plaque deposition before it begins.